AstraZeneca Launches ZEGFROVY in the US for NSCLC
AstraZeneca said ZEGFROVY is available in the US for adults with EGFR exon 20 insertion-mutated NSCLC after platinum chemotherapy. The FDA granted accelerated approval based on a 46% confirmed response rate in WU-KONG1B.
AstraZeneca said ZEGFROVY (sunvozertinib) is now available in the US for adults with EGFR exon 20 insertion-mutated NSCLC who have received platinum chemotherapy. The FDA granted accelerated approval based on a 46% confirmed response rate in WU-KONG1B.